Replies to post #95968 on Biotech Values

[poorgradstudent]

ONCY:

>Eligible patients include those who have been diagnosed with advanced or metastatic cancers including head, neck and esophageal tumours that are refractory (have not responded) to standard therapy or for which no curative standard therapy exists.<

Doesn't matter.

It's a fool's errand to put much stock in an uncontrolled trial of 20-30 patients in a disease as heterogeneous as cancer.

I've learned the hard way.